Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Raw Materials (2021 - 2024)

Apellis Pharmaceuticals has reported Raw Materials over the past 4 years, most recently at $42.1 million for Q1 2024.

  • Quarterly results put Raw Materials at $42.1 million for Q1 2024, up 23.98% from a year ago — trailing twelve months through Mar 2024 was $42.1 million (up 23.98% YoY), and the annual figure for FY2023 was $32.7 million, up 9.64%.
  • Raw Materials for Q1 2024 was $42.1 million at Apellis Pharmaceuticals, up from $32.7 million in the prior quarter.
  • Over the last five years, Raw Materials for APLS hit a ceiling of $42.1 million in Q1 2024 and a floor of $5.7 million in Q4 2021.
  • Median Raw Materials over the past 4 years was $28.0 million (2022), compared with a mean of $26.3 million.
  • Biggest five-year swings in Raw Materials: soared 419.17% in 2022 and later increased 0.75% in 2023.
  • Apellis Pharmaceuticals' Raw Materials stood at $5.7 million in 2021, then soared by 419.17% to $29.8 million in 2022, then grew by 9.64% to $32.7 million in 2023, then grew by 28.62% to $42.1 million in 2024.
  • The last three reported values for Raw Materials were $42.1 million (Q1 2024), $32.7 million (Q4 2023), and $26.2 million (Q3 2023) per Business Quant data.